Method validation

The validation report - content, structure and design tips

Written by Dr. Janet Thode Posted in Method validation

Having already written a blog article about the method validation plan and its contents some time ago and also created corresponding templates, today we’d like to address the question of what the method validation report (to be prepared after execution of the validation experiments) deals with, how it could be structured, and, above all, what makes a good report.

Linearity tests

Written by Dr. Janet Thode Posted in Method validation

Many analytical methods require calibration to determine the linear range. Linearity tests can be used to check whether the determined calibration function is actually linear.

Depending on the scope / “business area”, checking the linearity using linearity tests is also required for method validations or could at least be useful. In an earlier article, we looked at the relative response in this context.

In the meantime, however, I came across other linearity tests and we will have a look at these in today's article.

What does the ZLG Aide mémoire 07123101 "Inspection of analytical validation and method transfer" actually tell us?

Written by Dr. Janet Thode Posted in Method validation

Do you manage a QC laboratory in the pharmaceutical industry or a contract laboratory in Germany and are you due for the next inspection by the regional council? Then it may also be worth looking at the Aide mémoire AiM 07123101 "Inspection of analytical validation and method transfer", which was published by the Central Authority of the Federal States (“Länder”) for Health Protection with regard to Medicinal Products and Medical Devices (German: Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten, ZLG) in 2017.

In this blog article, we’d like to give a brief outline of what this ZLG inspection guideline tells us to do in terms of method validation and method transfer.

New potency assays for anti-VEGF antibodies

Written by Dr. Janet Thode Posted in Method validation

Introduction and Background

The group of vascular endothelial growth factors (VEGF) plays a crucial role in the formation of new blood vessels (angiogenesis), since they stimulate the growth, i.e. the division and migration of endothelial cells, as the name already suggests. Since some tumor types can better supply themselves with nutrients via increased angiogenesis and thus grow faster, anti-VEGF antibodies represent significant cancer therapeutics. However, the various types of cancer are not the only indication; enhanced angiogenesis is also important in certain eye diseases.

Anti-VEGF antibodies or fragments include bevacizumab (Avastin®), ranibizumab (Lucentis®) or aflibercept (Eylea®) and an increasing number of biosimilars already on the market and in late-stage clinical trials, such as Mvasi®, Zirabev® or BevaciRel®.